Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth

Commentary
Video

The clinical professor of neurology and pediatrics at Keck School of Medicine of USC also discussed current strategies with gene therapy administration.

“I think gene therapies in general are going to grow. If we look at the approvals that have happened, at first it was just Luxturna and then maybe onasemnogene... and then they just started taking off. I mean, last year, there were several that were approved. I'm listening to not just in neuromuscular, but also in epilepsy, neurodevelopmental disorders, all of these therapies that are coming out in the hematology world, in the leukodystrophy world. And I think it's going to be a very different experience as a pediatric medicine provider in the next 10 years. It's exciting. It's scary. I don't know how our systems are going to be able to handle all of these kinds of treatments. But it's always a learning experience."

As gene therapies become more common and grow in prevalence in the clinical space, it is important to strategize their administered in the clinic and examine current strategies for logistics of delivering gene therapies.Coordinating interdepartmental collaboration in centers delivering these therapies is also paramount, as well as ensuring informed consent.

Leigh Ramos-Platt, MD, Medical Director, Muscular Dystrophy Association Neuromuscular Clinic and attending physician, Division of Neurology, Children’s Hospital Los Angeles, and Clinical Professor of Neurology and Pediatrics, Keck School of Medicine, University of Southern California (USC), gave a talk around this topic at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, held March 3-6, in Orlando, Florida.

CGTLive® spoke with Ramos-Platt to learn more about some takeaways from the talk, including communication between parties and strategizing care as the most salient points. She also shared her excitement for the gene therapy space in general, which she has seen grow since her time in the field and expects to continue to grow in the near future.

REFERENCE
Ramos-Platt L. DMD Gene Therapy Day Of: Institutional and Patient/Family Readiness- When We Were Not a Trial Site. Presented at: 2024 MDA Clinical and Scientific Conference; March 3-6; Orlando, FL.
Related Videos
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
Ignacio Mata, PhD, an associate professor of neurology at the Cleveland Clinic Lerner Institute
© 2024 MJH Life Sciences

All rights reserved.